KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Resmed (RMD) over the last 4 years, with Q3 2021 value amounting to $8.5 million.

  • Resmed's Amortization of Deferred Charges fell 1827.86% to $8.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $32.9 million, marking a year-over-year increase of 604.54%. This contributed to the annual value of $34.8 million for FY2021, which is 3105.61% up from last year.
  • As of Q3 2021, Resmed's Amortization of Deferred Charges stood at $8.5 million, which was down 1827.86% from $9.0 million recorded in Q2 2021.
  • Resmed's Amortization of Deferred Charges' 5-year high stood at $10.4 million during Q3 2020, with a 5-year trough of $6.0 million in Q3 2019.
  • For the 3-year period, Resmed's Amortization of Deferred Charges averaged around $7.8 million, with its median value being $7.5 million (2020).
  • In the last 5 years, Resmed's Amortization of Deferred Charges surged by 7477.78% in 2020 and then crashed by 1827.86% in 2021.
  • Over the past 3 years, Resmed's Amortization of Deferred Charges (Quarter) stood at $6.4 million in 2019, then grew by 17.75% to $7.5 million in 2020, then increased by 13.73% to $8.5 million in 2021.
  • Its Amortization of Deferred Charges was $8.5 million in Q3 2021, compared to $9.0 million in Q2 2021 and $7.9 million in Q1 2021.